Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc
(NQ:
VRCA
)
2.350
-0.090 (-3.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verrica Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval
July 25, 2023
Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
July 25, 2023
Via
Benzinga
$1M Bet On Verrica Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
July 25, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
Recap: Verrica Pharmaceuticals Q1 Earnings
May 09, 2023
Verrica Pharmaceuticals (NASDAQ:VRCA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday
July 24, 2023
The company's shares dropped because it will require financing to help launch its first marketed product.
Via
The Motley Fool
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 24, 2023
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
July 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 24, 2023
Via
Benzinga
FDA Approves Verrica Pharma's Ycanth: First Treatment Of Molluscum Contagiosum Impacting 6M People In US
July 24, 2023
The FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients
Via
Benzinga
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
July 24, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
July 21, 2023
Via
Benzinga
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum
July 21, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
May 31, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
May 29, 2023
Via
Benzinga
Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
May 09, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
April 26, 2023
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers.
Via
InvestorPlace
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
April 12, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
March 22, 2023
Via
Benzinga
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
March 06, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
February 27, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 21, 2023
Via
Benzinga
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 21, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
2 Breakout Growth Stocks to Buy for the Long Haul
February 14, 2023
These two healthcare stocks have crushed the broader markets this year.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
February 13, 2023
Via
Benzinga
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
January 24, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
January 04, 2023
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
December 02, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.